ELAVL2 is a human gene whose product eLAVL2 is a member of the ELAVL family (ELAVL1-4) that is expressed specifically in neurons and primarily localizes to the cytoplasm. The protein contains multiple RNA recognition motifs (RRMs) that enable binding to specific sequences in target mRNAs. Variants in ELAVL2 have been implicated in Neurodegenerative Diseases, Alzheimer's Disease (AD), Parkinson's Disease (PD). This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration. [1]
ELAVL2 (ELAV Like RNA Binding Protein 2) is a neuron-specific RNA-binding protein that plays critical roles in post-transcriptional gene regulation, neuronal development, and synaptic plasticity. Also known as HuB, this gene belongs to the ELAVL family of RNA-binding proteins that recognize AU-rich elements (AREs) in messenger RNA (mRNA) 3' untranslated regions (UTRs), thereby influencing RNA stability, localization, and translation. [2]
| Property | Value | [3]
|----------|-------| [4]
| Full Name | ELAV Like RNA Binding Protein 2 | [5]
| Official Symbol | ELAVL2 | [6]
| Gene ID | 1993 (NCBI) | [7]
| Chromosomal Location | 9p21.3 |
| Protein | HuB protein |
| Protein Family | ELAVL (Embryonic Lethal, Abnormal Vision, Drosophila-like) |
| Molecular Weight | ~36-39 kDa |
ELAVL2 is a member of the ELAVL family (ELAVL1-4) that is expressed specifically in neurons and primarily localizes to the cytoplasm. The protein contains multiple RNA recognition motifs (RRMs) that enable binding to specific sequences in target mRNAs.
ELAVL2 regulates gene expression through several mechanisms:
mRNA Stability: Binds to AU-rich elements (AREs) in the 3' UTRs of target mRNAs, protecting them from degradation by exonucleases. Key targets include its own mRNA (autoregulation), FOS, ID proteins, and POU5F1.
Alternative Splicing: Influences the splicing patterns of pre-mRNA transcripts, contributing to transcript diversity in neuronal cells.
Translation Regulation: Modulates the translation efficiency of target mRNAs by facilitating or inhibiting ribosomal recruitment to the 5' cap structure.
mRNA Localization: Participates in the subcellular localization of specific mRNAs within neurons, enabling localized protein synthesis at synapses.
ELAVL2 is expressed specifically in neurons throughout the central nervous system, with high expression in:
The neuron-specific expression pattern distinguishes ELAVL2 from its paralogs ELAVL1 (HuR) and ELAVL3 (HuC), which have broader tissue distribution.
While ELAVL2 is not classically associated with monogenic neurodegenerative disorders, emerging research suggests roles in several neurodegenerative conditions:
RNA binding proteins including ELAVL2 have been implicated in AD pathogenesis through their effects on tau metabolism and amyloid precursor protein (APP) processing. Dysregulation of post-transcriptional regulators may contribute to:
ELAVL2 may influence PD through regulation of genes involved in:
Given the role of RNA metabolism in ALS, ELAVL2 dysfunction could contribute to:
ELAVL2 regulation of transcript expression is critical for neuronal function and has been clinically relevant to autism. Studies have identified ELAVL2 as a hub gene in neurodevelopmental disorders, with altered expression patterns in ASD brains.
Given its essential role in neuronal development and synaptic function, ELAVL2 variants may contribute to intellectual disability phenotypes through:
ELAVL2 interacts with several key proteins involved in RNA metabolism and neuronal function:
In neurodegenerative contexts, ELAVL2 expression patterns may be altered:
ELAVL2 and other neuronal ELAVL proteins represent potential therapeutic targets for neurodegenerative diseases:
Tirucherai et al. ELAVL2 in Neuronal Function (2020). 2020. ↩︎
Inoue et al. ELAVL2 in Neurodegeneration (2021). 2021. ↩︎
NCBI Gene: ELAVL2. 1993. ↩︎
Pascale et al. ELAV/Hu proteins and post-transcriptional regulation in the nervous system (2022). 2022. ↩︎
Bronicki et al. ELAVL2 in neurodevelopmental disorders (2015). 2015. ↩︎
Abdelmohsen et al. HuR and ELAVL2 in age-associated gene expression (2023). 2023. ↩︎
Sala et al. RNA binding proteins in neurodegenerative diseases (2024). 2024. ↩︎